May 14, 2019
Subscribe through iTunes and Google Play.
Welcome to this ASCO in Action podcast. This is ASCO's podcast series where we explore policy and practice issues that impact oncologists, the entire cancer care delivery team, and most importantly, the patients we care for, people with cancer. My name is Cliff Hudis. And I'm the CEO of ASCO, as well as the host of this ASCO in Action podcast series.
For today's podcast, we're going to do something a little
different. We don't have a guest today. Instead, we're going to
spend some time going over a quick update on an important
clarification issued recently by the CDC, the Center for Disease
Control and Prevention, and specifically, their guidelines for
prescribing opioids for chronic pain, a very topical issue.
The clarification they issued was the form of a letter from the
agency to ASCO, as well as to ASH and the NCCN. And in this letter,
the clarification affirmed that the CDC guideline was never
intended to deny access to clinically appropriate opioid therapy
for patients suffering with acute or chronic pain from conditions
like cancer and sickle cell disease.
But I want to explain first why it was important that they issue
this clarification and then talk about what we have to do next.
Opioid abuse in the United States is clearly a very serious issue.
And the tremendous toll that it's been extracting on individuals
and families across the nation is well-reported. Indeed, it was one
of the reasons originally given for the passage of the 21st Century
Cures Act. In fact, one of the motivations had to do with
addressing some parts of the opioid crisis.
And so this just makes the point that finding a solution to the
problem is among the very highest priorities that government and
really the general public, as well as professional societies and
advocacy groups and all stakeholders, have to be working
towards.
However, we do have to, at the same time, be careful that we don't
overreach and cause additional harm, especially to vulnerable
populations, as we take steps to reduce opioid abuse. What happened
before was that there was a misinterpretation of the opioid
prescribing recommendations that had been issued by the CDC.
And this resulted in part in new laws and regulations, as well as
third-party payment policies that severely limited essential pain
medications from patients with cancer and sickle cell disease. The
consequence for them was suffering and even more prolonged
hospitalizations and health care expenses.
So the challenge here was to fix this mistake. As we talk about how
this happened, I want to take a moment and provide a little bit of
background on this. Last spring, about a year ago I think, there
were papers published, at least one in particular, that highlighted
seeming discrepancies-- and I emphasize the word seeming-- between
opioid use guidelines that had been issued by the CDC, the NCCN,
ASCO, and others.
To their credit, the NCCN, led by Bob Carlson, responded to this by
reaching out to us at ASCO and asking if we would be willing to
collaborate on a meeting of the minds to identify what was true and
not true in terms of those supposedly conflicting guidelines and
then issue some sort of a unified statement to help address the
situation.
In November of 2018, hosted here at ASCO headquarters,
representatives from ASCO, the National Comprehensive Cancer
Network or NCCN, the American Society of Hematology, ASH, and the
CDC met to discuss the similarities, as well as the differences,
among our various published respective guidelines in the area of
managing chronic pain. We also discussed how to more clearly
communicate to all of our respective memberships how and when
practice guidelines should be applied in patient care.
While discussing the CDC guideline, it became very clear to all of
us that it was necessary to issue at some point a clarification on
the question of where the CDC guideline applied to patients with
cancer and sickle cell. And indeed, the first action item we took
after this November meeting was that ASCO, ASH, and the NCCN sent a
letter to the CDC asking for clarification.
We're really happy, again, to report that this collaboration
worked. Very soon after they received this letter from us, the CDC
responded favorably. And in their response letter, they noted that
their guideline, that is, the CDC's guideline, was initially
developed to provide recommendations for primary care clinicians
who prescribe opioids for patients with chronic pain outside of
active cancer treatment, outside of palliative care, and outside of
end of life care.
So I want to pause for just a second and make very clear the aim of
their original publication was primary care docs, not oncologists
or hematologists, and the patients they were talking about were by
and large not the patients who are seen and cared for in
oncologists' offices. So the letter really did clarify that the
CDC's guideline was never intended to deny clinically appropriate
opioid therapy to any patients with acute or chronic pain from
conditions like cancer and sickle cell disease.
But instead, it was intended to ensure that physicians and patients
consider all safe and effective treatment options for all patients
with pain. And underneath all this remained the shared goal of
reducing inappropriate use. Beyond this, the CDC also noted that
the treatment guidelines from disease-specific experts-- and that
means ASCO, NCCN, and ASH-- should be the guide to treatment and
reimbursement decisions in the specific circumstances they
cover.
So let's just spend another 30 seconds on this idea. They did issue
a guideline. It does apply to the general population. They never
intended for it to apply to cancer patients or sickle cell
patients. And they further called out in a sense the primacy of the
disease special list in terms of the guideline priority.
So it's great that we got this clarification. It's wonderful news.
But I would submit to you that it's really just the first step
towards ensuring that our patients don't suffer needlessly. So with
this clarification in hand, we can and I would say we must act
swiftly to correct existing policies that have already resulted in
some areas in blanket restrictions on opioid prescribing, again,
based on a misinterpretation over application of the CDC guideline.
Every single day that goes by, there are Americans who are
experiencing debilitating pain that could be avoided with
appropriate treatment. We have some evidence for this. In 2018, as
you may know, the American Cancer Society Cancer Action Network,
that's ACS CAN, reported that 30% of cancer patients and survivors
said that they were unable to obtain their prescribed opioid
medication because of insurance denials. And that was a significant
increase almost threefold from the 11% reported in 2016.
So if you remember what we were talking about a moment ago, here's
a set of guidelines that come out. They're not meant to be applied
to cancer patients. And yet, we saw that as they were being
misinterpreted and misapplied, there was a tripling in the number
of patients reporting trouble getting indicated medications, and I
mean cancer patients.
Furthermore, 48% of individuals with cancer reported that their
options for pain management were being limited by laws, guidelines,
or insurance coverage denials. So this was, again, an external hand
influencing their care coming from outside of their doctor's
office.
And even in states that exempt patients undergoing cancer
treatment, there are significant administrative hurdles that are
delaying access to much needed pain relief, not to mention that
such exemptions often excluded cancer survivors. And survivors can
have chronic pain for years sometimes from the disease or
treatment. And without that exemption, they would, in fact, be
suffering in a way that should be avoided.
So it goes without saying, but I'll say it, that we really
appreciate the CDC's leadership on this complex crisis. The agency
has rightly noted that the opioid epidemic will continue to need
ongoing collaboration and leadership. And we all need this as we
work towards resolving the crisis. But they also acknowledge the
importance of making sure that cancer patients and patients with
sickle cell disease get the care and caring that they need and they
deserve.
I'll also point out that the US Food and Drug Administration plays
an important role in advancing the use of evidence-based
prescribing guidelines so that they are able to more accurately and
appropriately direct the prescription of opioids. Former FDA
commissioner Dr. Scott Gottlieb recognized this. And we look
forward to continuing this important partnership with acting FDA
commissioner Dr. Ned Sharpless.
I think it's fair to say that the opioid crisis requires a response
that protects the public, limits abuse, and ensures access for
individuals who live with severe chronic pain. That's a vulnerable
group. Clinicians, legislators, regulators, insurers, guideline
developers, and patients have to join forces to make sure that we
establish sensible, evidence-based approaches that confront opioid
abuse but do not add a new group that suffers unnecessarily. We
don't want to have one national crisis become two.
So I want to close by extending my deepest appreciation to NCCN and
ASH for collaborating with us to address this critically important
issue and to ensure that our respective members are able to provide
the highest quality care that their patients expect and
deserve.
If you want more information on our efforts to ensure access to
appropriate pain control for patients with cancer and our other
policy priorities, please visit ASCO in Action on our website at
asco.org/ascoaction all one word. And until next time, I thank you
for listening to this ASCO in Action podcast.